B. Le Droumaguet et al. / International Journal of Pharmaceutics 416 (2011) 453–460
459
leading to their complete inaccessibility towards A1–42. More
importantly, this study points out the importance of the hydropho-
bicity/hydrophilicity of the selected ligand displayed at the surface
of polymeric NPs.
Acknowledgments
The research leading to these results has received funding
from the European Community’s Seventh Framework Programme
(FP7/2007-2013) under agreement no. 212043. The CNRS and the
French Ministry of Research are also warmly acknowledged for
financial support.
Fig. 6. Schematic representation describing the rearrangement of the seligiline lig-
ands at the surface of the seligiline-functionalized nanoparticles N3–N8.
the P(MePEGCA-co-SelPEGCA-co-HDCA) nanoparticles. This ineffi-
ciency of selegiline-functionalized nanoparticles towards binding
to the A1–42 peptide clearly demonstrated that the ligand was
not well exposed and probably inaccessible for efficient interac-
tion with A1–42 peptide which thus confirmed the hypothesis
postulated earlier in this study.
References
Aguzzi, A., O’Connor, T., 2010. Protein aggregation diseases: pathogenicity and ther-
apeutic perspectives. Nat. Rev. Drug Discov. 9, 237–248.
Aliev, G., Smith, M.A., de la Torre, J.C., Perry, G., 2004. Mitochondria as a primary
target for vascular hypoperfusion and oxidative stress in Alzheimer’s disease.
Mitochondrion 4, 649–663.
Indeed, taken together with previous zeta potential measure-
ments, these data indicate that, after a certain time, selegiline
ligands which were initially exposed at the surface of the nanoparti-
cles became not accessible anymore, likely due to rearrangement of
the SelPEG chains. The hydrophobic nature of selegiline and/or pos-
sible hydrophobic interaction between selegiline moieties could
hydrophobic interactions (Fig. 6). This would conduct to a dras-
tic change in the linear PEG density at the surface of the NPs, which
is believed to be an important parameter regarding their binding
to the A1–42 peptide (Brambilla et al., 2010b). This may certainly
explain why selegiline-functionalized NPs exhibited less binding
the lower the binding efficiency towards the A1–42 peptide which
is in good agreement with the expected decrease of the linear PEG
chain density (in contrast to PEG loops) at the surface of the NPs
for higher selegiline content (Fig. 6). The activity of nanoparticles
N8 is negligible if one considers the dramatic decrease of the A
monomer peak (within 3 h) in the case of non-functionalized NPs.
This weak activity is probably more related to remaining MePEG
chains at the surface of the NPs than to selegiline-PEG chains. We
believe that if there were some specific interactions in-between
the peptide and the exposed ligand, the variation of the peptide
monomer peak would have been more intense.
Birks, J., Grimley Evans, J., Iakovidou, V., Tsolaki, M., Holt, F.E., 2009. Rivastigmine
for Alzheimer’s disease. Cochrane Database Syst. Rev., CD001191.
Brambilla, D., Nicolas, J., Le Droumaguet, B., Andrieux, K., Marsaud, V., Couraud, P.-
O., Couvreur, P., 2010a. Design of fluorescently tagged poly(alkyl cyanoacrylate)
nanoparticles for human brain endothelial cell imaging. Chem. Commun. 46,
2602–2604.
Brambilla, D., Verpillot, R., Taverna, M., De Kimpe, L., Le Droumaguet, B., Nico-
las, J., Mantegazza, F., Canovi, M., Gobbi, M., Salmona, M., Nicolas, V.,
Scheper, W., Couvreur, P., Andrieux, K., 2010b. Capillary electrophoresis with
laser-induced fluorescence detection (CE-LIF) as a new protocol to monitor
interaction between nanoparticles and the amyloid- peptide. Anal. Chem. 82,
10083–10089.
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., D’Angelo, J., Noel, J.-P., Georgin,
D., Fattal, E., Andreux, J.P., Couvreur, P., 2001. Long-circulating PEGylated poly-
cyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res.
18, 1157–1166.
Carter, D.B., Chou, K.C., 1998. A model for structure-dependent binding of Congo red
to Alzheimer -amyloid fibrils. Neurobiol. Aging 19, 37–40.
Chow, V., Mattson, M., Wong, P., Gleichmann, M., 2010. An overview of APP process-
ing enzymes and products. Neuromol. Med. 12, 1–12.
Christopher, D.L., Carolyn, J.J., Virginia, F., Marie-Christine, P., David, H.H., Scot, S.,
Chester, A.M., William, E.K., 2001. Visualization of fibrillar amyloid deposits in
living, transgenic Caenorhabditis elegans animals using the sensitive amyloid
dye, X-34. Neurobiol. Aging 22, 217–226.
Colombo, R., Carotti, A., Catto, M., Racchi, M., Lanni, C., Verga, L., Caccialanza, G.,
De Lorenzi, E., 2009. CE can identify small molecules that selectively target
soluble oligomers of amyloid  protein and display antifibrillogenic activity.
Electrophoresis 30, 1418–1429.
de la Torre, J.C., 2004. Is Alzheimer’s disease a neurodegenerative or a vascular
disorder? Data, dogma, and dialectics. Lancet Neurol. 3, 184–190.
Dezutter, N.A., de Groot, T.J., Busson, R.H., Janssen, G.A., Verbruggen, A.M., 1999a.
Preparation of 99mTc-N2S2 conjugates of Chrysamine G, potential probes for the
beta-amyloid protein of Alzheimer’s disease. J. Labelled Compd. Radiopharm.
42, 309–324.
Dezutter, N.A., Dom, R.J., de Groot, T.J., Bormans, G.M., Verbruggen, A.M., 1999b.
99mTc-MAMA-Chrysamine G, a probe for beta-amyloid protein of Alzheimer’s
disease. Eur. J. Nucl. Med. Mol. Imaging 26, 1392–1399.
4. Conclusion
Garcia-Alloza, M., Borrelli, L.A., Rozkalne, A., Hyman, B.T., Bacskai, B.J., 2007. Cur-
cumin labels amyloid pathology in vivo, disrupts existing plaques, and partially
restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 102,
1095–1104.
Garcia-Garcia, E., Andrieux, K., Gil, S., Couvreur, P., 2005a. Colloidal carriers and
blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain?
Int. J. Pharm. 298, 274–292.
This study investigated the potential binding activity of poly-
meric selegiline-functionalized, PEGylated poly(alkyl cyanoacry-
late) nanoparticles to the A1–42 peptide, a biomarker of the
Alzheimer’s disease. Whereas
a poor colloidal stability was
obtained with the pure selegiline-functionalized copolymer, best
stability conditions were obtained after simultaneous nanoprecip-
itation of this polymer with the rhodamine-labelled, PEGylated
poly(alkyl cyanoacrylate) copolymer species in variable ratios. It
allowed the amount of selegiline moieties initially displayed at
the surface of the NPs to be finely tuned. Although the size of
the selegiline-functionalized NPs remained constant with time,
the value of the zeta potential drastically decreased. This was
confirmed by capillary electrophoresis which showed a lower
interaction of selegiline decorated nanoparticles towards A1–42
comparatively to the non-functionalized nanoparticles. A possi-
ble explanation was proposed and relied on a rearrangement
of functionalized selegiline chains at the surface of the NPs
Garcia-Garcia, E., Gil, S., Andrieux, K., Desmaële, D., Nicolas, V., Taran, F., Georgin, D.,
Andreux, J., Roux, F., Couvreur, P., 2005b. A relevant in vitro rat model for the
evaluation of blood–brain barrier translocation of nanoparticles. Cell. Mol. Life
Sci. 62, 1400–1408.
García-Matas, S., de Vera, N., Aznar, A.O., Marimon, J.M., Adell, A., Planas, A.M., Cristò-
fol, R., Sanfeliu, C., 2010. In vitro and in vivo activation of astrocytes by amyloid-
is potentiated by pro-oxidant agents. J. Alzheimer’s Dis. 20, 229–245.
Gralle, M., Botelho, M.G., Wouters, F.S., 2009. Neuroprotective secreted amyloid pre-
cursor protein acts by disrupting amyloid precursor protein dimers. J. Biol. Chem.
284, 15016–15025.
Kato, M., Kinoshita, H., Enokita, M., Hori, Y., Hashimoto, T., Iwatsubo, T., Toyo’oka,
T., 2007. Analytical method for -amyloid fibrils using CE-laser induced fluo-
rescence and its application to screening for inhibitors of -amyloid protein
aggregation. Anal. Chem. 79, 4887–4891.
Kemp, J.A., McKernan, R.M., 2002. NMDA receptor pathways as drug targets. Nat.
Neurosci. 5, 1039–1042.